The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Clinical trial NCT03384511 · COMPLETED
Trial details
- NCT number
- NCT03384511
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-30
- Primary completion
- 2018-01-28
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.